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Neuroendocrine neoplasms of the pancreas, also known as islet cell 
tumors, are relatively rare, although they are diagnosed with increasing 
incidence and high prevalence (1). Because of their overall indolent 
but malignant course, pancreatic neuroendocrine neoplasms have not 
been well studied, and standard staging tools have been lacking (2).
A TNM staging system for neuroendocrine neoplasms of the 
pancreas was proposed for the first time in the year 2006 by the 
European Neuroendocrine Tumor Society (ENETS TNM) (3). 
More recently, the International Union for Cancer Control devel-
oped a TNM staging system, which is now endorsed by both the 
American Joint Cancer Committee and the World Health 
Organization (UICC/AJCC/WHO 2010 TNM) (4–6).
However, the tumor definition and derived stages of the 
ENETS TNM and the UICC/AJCC/WHO 2010 TNM staging 
systems greatly differ (Table 1). Specifically, the UICC/AJCC/
WHO 2010 TNM is the same as for the ductal adenocarcinoma 
and is not meant for high-grade neuroendocrine neoplasms. The 
ENETS TNM is based on the published experience of single 
centers and not on a uniform database; since its earliest publication, 
it has been validated by at least six independent series (7–12). In 
contrast, the UICC/AJCC/WHO 2010 TNM is built on a cancer 
registry database publication and is thus based on somewhat 
limited data (13). Recently, this system was validated on a mono-
institutional series (14).
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 Background Both the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer Control/
American Joint Cancer Committee/World Health Organization (UICC/AJCC/WHO) have proposed TNM staging 
systems for pancreatic neuroendocrine neoplasms. This study aims to identify the most accurate and useful 
TNM system for pancreatic neuroendocrine neoplasms.
 Methods The study included 1072 patients who had undergone previous surgery for their cancer and for which at least 
2 years of follow-up from 1990 to 2007 was available. Data on 28 variables were collected, and the performance 
of the two TNM staging systems was compared by Cox regression analysis and multivariable analyses. All 
statistical tests were two-sided.
 Results Differences in distribution of sex and age were observed for the ENETS TNM staging system. At Cox regression 
analysis, only the ENETS TNM staging system perfectly allocated patients into four statistically significantly 
different and equally populated risk groups (with stage I as the reference; stage II hazard ratio [HR] of death = 
16.23, 95% confidence interval [CI] = 2.14 to 123, P = .007; stage III HR of death = 51.81, 95% CI = 7.11 to 377, 
P < .001; and stage IV HR of death = 160, 95% CI = 22.30 to 1143, P < .001). However, the UICC/AJCC/WHO 2010 
TNM staging system compressed the disease into three differently populated classes, with most patients in 
stage I, and with the patients being equally distributed into stages II–III (statistically similar) and IV (with stage 
I as the reference; stage II HR of death = 9.57, 95% CI = 4.62 to 19.88, P < .001; stage III HR of death = 9.32, 95% 
CI = 3.69 to 23.53, P = .94; and stage IV HR of death = 30.84, 95% CI = 15.62 to 60.87, P < .001). Multivariable 
modeling indicated curative surgery, TNM staging, and grading were effective predictors of death, and grading 
was the second most effective independent predictor of survival in the absence of staging information. Though 
both TNM staging systems were independent predictors of survival, the UICC/AJCC/WHO 2010 TNM stages 
showed very large 95% confidence intervals for each stage, indicating an inaccurate predictive ability.
 Conclusion Our data suggest the ENETS TNM staging system is superior to the UICC/AJCC/WHO 2010 TNM staging system 
and supports its use in clinical practice.
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The presence of two different TNM systems raised concerns of 
potential confusion in patient management (15,16). The aim of our 
study was to provide information on use of the two systems by a 
head-to-head comparison using a large, international single database. 
In addition, the predictive ability of the ENETS/WHO 2010 
histological grading for digestive NETs and of several other relevant 
clinical–pathological variables was assessed.
Materials and Methods
Data Collection
Eight European cancer centers provided data on pancreatic 
neuroendocrine neoplasms. The centers were selected because 
they had either already published their series to test the ENETS 
TNM or have previously published studies on pancreatic neuro-
endocrine neoplasms. Data from 1072 neoplasms from the 
following centers were included in the analysis: Verona-Roma 
(n = 365 neoplasms) (12), Berlin-Charité (n = 170 neoplasms) 
(10), Varese-Milano San Raffaele-Pavia (n = 144 neoplasms) (9), 
Heidelberg (n = 118 neoplasms) (8), Zurich (n = 114 neoplasms), 
Clichy (n = 111 neoplasms), London-UCL (n = 32 neoplasms), 
and Erasmus-Rotterdam (n = 18 neoplasms). None of the neo-
plasms analyzed in this study has been analyzed in previously 
published reports aiming at the development of the ENETS 
TNM system. The internal ethics committees of each center gave 
their approval for the study. The study enrollment criteria included 
the following: the patient had undergone surgery for their cancer, 
and at least 2 years of follow-up data were available; as well, the 
patient had been under observation for at least 2 years during 
1990–2007. We analyzed 27 variables including age, sex, ethnicity, 
date of diagnosis, date of last follow-up, time of follow-up, status 
at last follow-up, curative surgery, genetic status, site, number of 
lesions, functioning tumor, type of syndrome, WHO 2000 class, 
ENETS-WHO 2010 grading (17), mitotic count, Ki67 index, 
size, ENETS TNM Stage, ENETS T (tumor definition), N 
(lymph node status), number of lymph nodes, M (distant metastases), 
CONTEXT AND CAVEATS
Prior knowledge
Two TNM staging systems for pancreatic neuroendocrine neo-
plasms have been proposed by the European Neuroendocrine 
Tumor Society (ENETS) and the International Union for Cancer 
Control/American Joint Cancer Committee /World Health Organization 
(UICC/AJCC/WHO), respectively.
Study design
Data from 1072 patients who underwent surgery for neuroendocrine 
neoplasms of the pancreas were used to compare the performance 
of the two TNM staging systems.
Contribution
Unlike the UICC/AJCC/WHO 2010 TNM staging system, the patients 
were divided into four different and equally populated risk groups 
when the ENETS TNM staging system was used. Both TNM staging 
systems were found to be independent predictors of survival, 
although the UICC/AJCC/WHO 2010 TNM staging system was 
observed to have inaccurate predictive ability.
Implication
The ENETS TNM staging system should be the preferred method 
for staging pancreatic neuroendocrine neoplasms.
Limitations
Because this was a retrospective study, there may have been some 
variation in the methods used when the data was collected. Also, 
variability in the pathologists and treatments at different institutions 
may also be present in the dataset.
From the Editors
 
Table 1. T and stage definitions in the European Neuroendocrine Tumor Society (ENETS) and the International Union for Cancer 
Control/American Joint Cancer Committee/World Health Organization (UICC/AJCC/WHO) 2010 TNM staging systems (3–6)*
Definitions ENETS TNM UICC/AJCC/WHO 2010 TNM
T definition  
 T1 Limited to the pancreas, <2 cm Limited to the pancreas, ≤2 cm in greatest dimension
 T2 Limited to the pancreas, 2–4 cm Limited to the pancreas, >2 cm in greatest dimension
 T3 Limited to the pancreas, >4 cm or invading  
 duodenum or bile duct
Beyond the pancreas but without involvement of the  
 superior mesenteric artery
 T4 Tumor invading adjacent organs (stomach, spleen,  
 colon, adrenal gland) or the wall of large vessels  
 (celiac axis or the superior mesenteric artery)
Involvement of celiac axis or the superior mesenteric  
 artery (unresectable tumor)
Stage definition  
 Stage I T1, N0, M0 NA
 Stage IIa T2, N0, M0 NA
 Stage IIb T3, N0, M0 NA
 Stage IIIa T4, N0, M0 NA
 Stage IIIb Any T, N1, M0 NA
 Stage IV Any T, any N, M1 NA
 Stage IA NA T1, N0, M0
 Stage IB NA T2, N0, M0
 Stage IIA NA T3, N0, M0
 Stage IIB NA T1–T3, N1, M0
 Stage III NA T4, any N, M0
 Stage IV NA Any T, any N, M1
* NA = not applicable.
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M site, UICC/AJCC/WHO 2010 TNM Stage, UICC/AJCC/
WHO 2010 T (tumor definition), type of surgery. Particular 
attention was paid to homogenous pathology assessment accord-
ing to the ENETS Guidelines, ENETS/WHO 2010 grading, and 
WHO 2000 classification (6,18). Deaths were classified as related 
to the underlying tumor by each hospital center based on each 
patient’s medical chart. Tumor-related death was defined as death 
directly or indirectly (eg, therapy-related mortality) associated 
with the pancreatic neuroendocrine neoplasm. Empty electronic 
datasheets with instructions were provided to participating 
centers and, on compilation, were centrally reviewed by G. Rindi 
and C. Klersy.
The first data round collection was completed by October 
2009. All data were cross-checked for inconsistencies by G. Rindi 
and C. Klersy. When necessary, centers were directly asked to 
clarify or amend the records. The whole database was revised by 
representatives from the participating centers during a dedicated 
session of the ENETS Advisory Board Meeting held in Rome, 
Italy, on November 11–13, 2009. Further important details were 
requested in a second round of data collection, and complete data-
sheets were submitted during the first half of the year 2010. Every 
effort was made to minimize missing or incomplete data.
Statistical Analysis
Continuous data were described as the mean and standard devia-
tion (SD) or median and 25th to 75th percentiles and were com-
pared by Kruskall–Wallis tests. Categorical data were described as 
counts and percentages and were compared by x2 tests. Median 
follow-up was calculated by the inverse Kaplan–Meier method. 
Tumor-related death was calculated and follow-up time was deter-
mined from the date of diagnosis to the date of tumor-related 
death or the last follow-up for survivors, and tumor-related death-
free survival was estimated with the Kaplan–Meier method. 
Patients dying from causes other than their cancer were censored 
at their date of death. Death rates per 100 person-years were 
reported. The Cox model was used to assess the prognostic value 
of a series of patient and tumor characteristics. Hazard ratios 
(HRs) and 95% confidence intervals (CIs) were also calculated. 
The proportional hazard assumption (Schoenfeld residuals) was 
always satisfied, and model fit was assessed graphically with 
Cox–Snell residuals.
The performance of the two TNM systems was informally 
compared through Royston explained variation and the Harrell C 
or the Somer D discrimination statistics in which the higher value 
was representative of better system performance. The model was 
fitted on a training sample and validated in a testing sample, after 
a random 1:1 split of the case series (19,20). Only cancers with data 
for both TNM systems were used for head-to-head comparative 
tests.
To identify the optimal cutoff for predicting 5-year tumor 
mortality for cancers by tumor size, number of positive lymph 
nodes, mitotic count, and Ki67 index, receiver operating curve 
(ROC) analysis was performed. Cox models for these variables, 
dichotomized by the identified optimal cutoffs, were fitted over the 
entire follow-up in the training sample, and the performance of the 
dichotomized variable was assessed on the testing sample by means 
of the Harrell C statistic.
Given the collinearity of ENETS, the UICC/AJCC/WHO 
2010 stage, and the WHO 2000 class, different multivariable 
models were fitted including either one of the three variables while 
also controlling for other noncollinear predictors for which P was 
less than .1 for the univariable analysis. Model validation and 
informal comparisons were on the basis of the Royston and 
explained variation, shrinkage coefficient (for calibration), and the 
Harrell C statistic (for discrimination) (20). Graphical discrimina-
tion was assessed by plotting the Kaplan–Meier curves by the 
tertiles of the distribution of the predictor index (linear combina-
tion of predictors) obtained from each model. The lower tertile 
identified patients at low risk of dying from their tumor, the 
middle tertile included patients with intermediate risk, and the 
upper tertile included patients at high risk. The Akaike infor-
mation criterion was also computed, the lower value indicating 
the better performance of the model (21). A series of sensitivity 
analyses were done to assess the robustness of our conclusions 
regarding ENETS TNM and UICC/AJCC/WHO 2010 staging 
systems. We assessed the role of both TNM systems on tumor-
free survival for each center separately, and with Cox models 
stratified by center, age, and/or sex, as well as the role of both 
classifications on overall survival. Analysis by race/ethnicity was 
done, but the data are not reported here because only limited 
information was obtained.
Data were analyzed with Stata (version 11; Stata Corporation, 
College Station, TX) and MedCalc (version 11; MedCalc Software, 
Mariakerke, Belgium). A two-sided P value of less than .05 was 
considered statistically significant. All statistical tests were 
two-sided.
Results
Emerging Clinicopathologic Features
The clinicopathologic data at diagnosis for patients included in the 
study are summarized in Table 2. Of 1072 patients included in the 
database, 503 (46.9%) were male. The mean age was 53 years 
(SD = 14 years). A median of 116 patients was enrolled in each 
Center (25th to 75th percentiles = 71–157 patients). One-third of 
the patients had a functioning neoplasm, of which insulinoma was 
the most frequent (67.1%). The tumor site was evenly distributed 
between head, body, and body–tail, with a small minority of 
patients (17 [1.8%] of 1072 patients) having whole-organ involve-
ment (head–body–tail). Curative surgery was performed in 74.9% 
of patients. Few patients were in WHO 2000 class 3 (70 patients, 
6.78%) and in ENETS/WHO 2010 grade G3 (63 patients, 
6.75%). All ENETS and UICC/AJCC/WHO 2010 TNM stages 
were observed among the study cohort. Some differences in 
distribution by sex and age were observed across the ENETS 
TNM staging system, which persisted for age only after high-grade 
neoplasms were excluded, as required by the UICC/AJCC/WHO 
2010 TNM staging system (Table 2).
Sporadic neoplasms were more frequent in older patients, 
whereas the multiple endocrine neoplasia syndrome type 1 genetic 
variant was more frequent among younger patients (P < .001). No 
differences in genetic status were observed between males and 
females. A functioning neoplasm was more often observed among 
females vs males (P = .02) and younger vs older patients (P = .01). 
jnci.oxfordjournals.org   JNCI | Articles 767
T
ab
le
 2
. C
lin
ic
al
 a
n
d
 p
at
h
o
lo
g
ic
al
 f
ea
tu
re
s 
o
f 
p
an
cr
ea
ti
c 
n
eu
ro
en
d
o
cr
in
e 
n
eo
p
la
sm
s 
at
 t
h
e 
ti
m
e 
o
f 
d
ia
g
n
o
si
s 
b
y 
se
x 
an
d
 a
g
e 
g
ro
u
p
V
ar
ia
b
le
N
o
. o
f 
va
lid
  
n
eo
p
la
sm
s
A
ll
S
ex
A
g
e
M
al
e 
 
(n
 =
 5
03
)
Fe
m
al
e 
 
(n
 =
 5
69
)
P
*
<4
8 
y 
 
(n
 =
 3
81
)
48
–6
1 
y 
 
(n
 =
 3
44
)
>6
1 
y 
 
(n
 =
 3
47
)
P
*
M
ea
n
 a
g
e,
 y
 (
S
D
)
10
72
53
.0
 (1
4.
3)
53
.6
 (1
4.
1)
52
.5
 (1
4.
5)
.2
5
N
A
N
A
N
A
N
A
S
ex
, N
o
. (
%
)
10
72
10
72
50
3 
(4
6.
9)
56
9 
(5
3.
1)
N
A
16
8 
(4
4.
1)
16
4 
(4
7.
7)
17
1 
(4
9.
3)
0.
35
G
en
et
ic
 s
ta
tu
s,
 N
o
. (
%
)
92
4
 
 
 
.2
9
 
 
 
<
.0
01
 
M
ul
tip
le
 e
nd
oc
rin
e 
ne
op
la
si
a 
sy
nd
ro
m
e 
ty
pe
 1
 
36
 (3
.9
)
12
 (2
.8
)
24
 (4
.7
9)
 
30
 (8
.9
)
4 
(1
.4
)
2 
(0
.7
)
 
V
on
 H
ip
pe
l–
Li
nd
au
 s
yn
dr
om
e
 
14
 (1
.5
)
6 
(1
.4
)
8 
(1
.6
)
 
12
 (3
.6
)
2 
(0
.7
)
0 
(0
.0
)
 
S
po
ra
di
c
 
87
4 
(9
4.
6)
40
5 
(9
5.
7)
46
9 
(9
3.
6)
 
29
5 
(8
7.
5)
28
6 
(9
7.
5)
29
3 
(9
9.
3)
Fu
n
ct
io
n
in
g
 t
u
m
o
r,
 N
o
. (
%
)
10
72
33
1 
(3
0.
9)
13
8 
(2
7.
4)
19
3 
(3
3.
9)
.0
2
13
9 
(3
6.
5)
96
 (2
7.
9)
96
 (2
7.
7)
.0
1
T
yp
e 
o
f 
sy
n
d
ro
m
e,
 N
o
. (
%
)
33
1
 
 
 
.5
7
 
 
 
.0
4
 
C
ar
ci
no
id
 
15
 (4
.5
)
7 
(5
.1
)
8 
(4
.1
)
 
3 
(2
.2
)
3 
(3
.1
)
9 
(9
.4
)
 
G
lu
ca
go
no
m
a
 
22
 (6
.6
)
11
 (8
.0
)
11
 (5
.7
)
 
3 
(2
.2
)
10
 (1
0.
4)
9 
(9
.4
)
 
In
su
lin
om
a
 
22
2 
(6
7.
1)
92
 (6
6.
7)
13
0 
(6
7.
4)
 
10
2 
(7
3.
4)
63
 (6
5.
5)
57
 (5
9.
04
)
 
V
er
ne
r–
M
or
ris
on
 
19
 (5
.7
)
10
 (7
.2
)
9 
(4
.7
)
 
8 
(5
.8
)
6 
(6
.2
)
5 
(5
.2
)
 
Zo
lli
ng
er
–E
lli
so
n
 
37
 (1
1.
2)
14
 (1
0.
1)
23
 (1
1.
9)
 
18
 (1
2.
9)
10
 (1
0.
4)
9 
(9
.4
)
 
O
th
er
†
 
16
 (4
.8
)
4 
(2
.9
)
12
 (6
.2
)
 
5 
(3
.6
)
4 
(4
.2
)
7 
(7
.3
)
C
u
ra
ti
ve
 s
u
rg
er
y,
 N
o
. (
%
)
10
49
78
6 
(7
4.
9)
34
0 
(6
9.
2)
44
6 
(7
9.
9)
<
.0
01
28
4 
(7
7.
2)
25
4 
(7
5.
1)
24
8 
(7
2.
3)
.3
2
T
yp
e 
o
f 
su
rg
er
y,
 N
o
. (
%
)
10
72
 
 
 
<
.0
01
 
 
 
.0
7
 
E
nu
cl
ea
tio
n
 
18
6 
(1
7.
3)
65
 (1
2.
9)
12
1 
(2
1.
3)
 
83
 (2
1.
8)
49
 (1
4.
2)
54
 (1
5.
6)
 
Le
ft
 p
an
cr
ea
te
ct
om
y
 
35
5 
(3
3.
1)
17
0 
(3
3.
8)
18
5 
(3
2.
5)
 
11
3 
(2
9.
7)
12
6 
(3
6.
6)
11
6 
(3
3.
4)
 
M
id
dl
e 
pa
nc
re
at
ec
to
m
y
 
69
 (6
.4
)
24
 (4
.8
)
45
 (7
.9
)
 
26
 (6
.8
)
22
 (6
.4
)
21
 (6
.0
)
 
P
an
cr
ea
tic
 d
uo
de
ne
ct
om
y/
W
hi
pp
le
 r
es
ec
tio
n
 
25
2 
(2
3.
5)
12
9 
(2
5.
6)
12
3 
(2
1.
6)
 
88
 (2
3.
1)
86
 (2
5.
0)
78
 (2
2.
5)
 
To
ta
l p
an
cr
ea
te
ct
om
y
 
29
 (2
.7
)
13
 (2
.6
)
16
 (2
.8
)
 
15
 (3
.9
)
7 
(2
.0
)
7 
(2
.0
)
 
U
nk
no
w
n
 
18
1 
(1
6.
9)
10
2 
(2
0.
3)
79
 (1
3.
9)
 
56
 (1
4.
7)
54
 (1
5.
7)
71
 (2
0.
5)
N
o
. o
f 
tu
m
o
rs
, m
ed
ia
n
 (
25
th
 t
o
 7
5t
h
 p
er
ce
n
ti
le
)
92
2
1 
(1
-1
)
N
A
N
A
N
A
N
A
N
A
N
A
N
A
M
u
lt
ip
le
 t
u
m
o
rs
, N
o
. (
%
)
92
2
47
 (5
.1
)
16
 (3
.8
)
31
 (6
.2
)
.1
0
28
 (8
.4
)
13
 (4
.3
)
6 
(2
.1
)
.0
01
T
u
m
o
r 
si
te
, N
o
. (
%
)
94
4
 
 
 
<
.0
01
 
 
 
.0
2
 
B
od
y
 
21
8 
(2
3.
1)
87
 (2
0.
1)
13
1 
(2
5.
6)
 
71
 (2
1.
3)
72
 (2
2.
9)
75
 (2
5.
3)
 
B
od
y–
ta
il
 
33
8 
(3
5.
8)
15
7 
(3
6.
3)
18
1 
(3
5.
4)
 
11
6 
(3
4.
7)
11
8 
(3
7.
6)
10
4 
(3
5.
1)
 
H
ea
d
 
37
1 
(3
9.
3)
18
8 
(4
3.
4)
18
3 
(3
5.
8)
 
13
4 
(4
0.
1)
12
1 
(3
8.
5)
11
6 
(3
9.
2)
 
H
ea
d–
bo
dy
–t
ai
l
 
17
 (1
.8
)
1 
(0
.2
)
16
 (3
.1
)
 
13
 (3
.9
)
3 
(1
.0
)
1 
(0
.3
)
T
u
m
o
r 
si
ze
, m
ed
ia
n
 (
25
th
 t
o
 7
5t
h
 p
er
ce
n
ti
le
),
 c
m
10
01
3.
0 
(1
.5
–5
.0
)
3.
0 
(1
.6
–5
.0
)
2.
5 
(1
.5
–5
.0
)
.0
3
2.
5 
(1
.5
–4
.5
)
3.
0 
(1
.5
–5
.0
)
3.
0 
(1
.5
–5
)
.0
9
W
H
O
 2
00
0 
cl
as
s,
 N
o
. (
%
)‡
10
33
 
 
 
<
.0
01
 
 
 
.0
05
 
1 
(W
D
E
T)
 
47
5 
(4
6.
0)
19
7 
(4
0.
5)
27
8 
(5
0.
8)
 
19
5 
(5
2.
8)
12
8 
(3
8.
5)
15
2 
(4
5.
8)
 
2 
(W
D
E
C
)
 
48
8 
(4
7.
2)
24
3 
(5
0.
0)
24
5 
(4
4.
8)
 
15
1 
(4
0.
9)
18
1 
(5
4.
2)
15
6 
(4
7.
0)
 
3 
(P
D
E
C
)
 
70
 (6
.8
)
46
 (9
.5
)
24
 (4
.4
)
 
23
 (6
.2
)
23
 (6
.9
)
24
 (7
.2
)
M
it
o
ti
c 
co
u
n
t,
 m
ed
ia
n
 (
25
th
 t
o
 7
5t
h
 p
er
ce
n
ti
le
)§
42
6
1 
(0
–3
)
1 
(0
–3
)
1 
(0
–3
)
.1
0
1 
(0
–3
)
1 
(0
–3
)
1 
(0
–2
)
.0
6
K
i6
7 
in
d
ex
, m
ed
ia
n
 (
25
th
 t
o
 7
5t
h
 p
er
ce
n
ti
le
)§
89
2
2 
(1
–6
)
2 
(1
–8
)
2 
(1
–5
)
<
.0
01
2 
(1
–5
)
2 
(1
–6
)
2 
(1
–7
)
.6
1
P
o
si
ti
ve
/a
ss
es
se
d
 ly
m
p
h
 n
o
d
es
, N
o
. (
%
)
33
5
 
 
 
.2
6
 
 
 
0.
44
 
0%
 
17
6 
(5
2.
5)
73
 (4
8.
3)
10
3 
(5
6.
0)
 
68
 (5
2.
7)
58
 (5
0.
0)
50
 (5
5.
6)
 
1%
–1
6%
 
52
 (1
5.
5)
23
 (1
5.
2)
29
 (1
5.
8)
 
26
 (2
0.
2)
20
 (1
7.
2)
6 
(6
.7
)
 
≥1
7%
 
10
7 
(3
1.
9)
55
 (3
6.
4)
52
 (2
8.
3)
 
35
 (2
7.
1)
38
 (3
2.
8)
34
 (3
7.
8)
E
N
E
T
S
/W
H
O
 2
01
0 
g
ra
d
e,
 N
o
. (
%
)
93
3
 
 
 
.0
06
 
 
 
0.
44
 
G
1
 
48
8 
(5
2.
3)
20
3 
(4
8.
1)
28
5 
(5
5.
8)
 
17
7 
(5
2.
2)
15
2 
(5
0.
5)
15
9 
(5
4.
3)
 
G
2
 
38
2 
(4
0.
9)
18
0 
(4
2.
6)
20
2 
(3
9.
5)
 
14
5 
(4
2.
8)
12
5 
(4
1.
5)
11
2 
(3
8.
2)
 
G
3
 
63
 (6
.8
)
39
 (9
.2
)
24
 (4
.7
)
 
17
 (5
.0
)
24
 (8
.0
)
22
 (7
.5
)
(T
ab
le
 c
on
tin
ue
s)
768   Articles | JNCI Vol. 104, Issue 10  |  May 16, 2012
V
ar
ia
b
le
N
o
. o
f 
va
lid
  
n
eo
p
la
sm
s
A
ll
S
ex
A
g
e
M
al
e 
 
(n
 =
 5
03
)
Fe
m
al
e 
 
(n
 =
 5
69
)
P
*
<4
8 
y 
 
(n
 =
 3
81
)
48
–6
1 
y 
 
(n
 =
 3
44
)
>6
1 
y 
 
(n
 =
 3
47
)
P
*
S
ta
g
e,
 N
o
. (
%
)
 
 
 
 
 
 
 
A
ll 
ne
op
la
sm
s
 
 
 
 
 
 
 
 
 
 
E
N
E
TS
10
34
 
 
 
.0
3
 
 
 
.0
3
 
 
 
I
 
29
0 
(2
8.
0)
11
2 
(2
3.
2)
17
8 
(3
2.
2)
 
11
5 
(3
1.
5)
87
 (2
6.
4)
88
 (2
5.
9)
 
 
 
IIA
 
14
6 
(1
4.
1)
67
 (1
3.
9)
79
 (1
4.
1)
 
62
 (1
7.
0)
35
 (1
0.
6)
49
 (1
4.
4)
 
 
 
IIB
 
77
 (7
.4
)
36
 (7
.5
)
41
 (7
.4
)
 
27
 (7
.4
)
17
 (5
.2
)
33
 (9
.7
)
 
 
 
III
A
 
39
 (3
.8
)
21
 (4
.4
)
18
 (3
.3
)
 
10
 (2
.7
)
13
 (3
.9
)
16
 (4
.7
)
 
 
 
III
B
 
19
8 
(1
9.
2)
98
 (2
0.
3)
10
0 
(1
8.
1)
 
64
 (1
7.
5)
69
 (2
1.
0)
65
 (1
9.
1)
 
 
 
IV
 
28
4 
(2
7.
5)
14
8 
(3
0.
7)
13
6 
(2
4.
6)
 
87
 (2
3.
8)
10
8 
(3
2.
8)
89
 (2
6.
2)
 
 
U
IC
C
/A
JC
C
/W
H
O
 2
01
0
90
3
 
 
 
.0
7
 
 
 
.2
6
 
 
 
IA
 
26
6 
(2
9.
5)
10
3 
(2
5.
3)
16
3 
(3
2.
9)
 
10
6 
(3
2.
6)
81
 (2
7.
9)
79
 (2
7.
4)
 
 
 
IB
 
14
2 
(1
5.
7)
59
 (1
4.
5)
83
 (1
6.
7)
 
56
 (1
7.
2)
37
 (1
2.
8)
49
 (1
7.
0)
 
 
 
IIA
 
71
 (7
.9
)
38
 (9
.3
)
33
 (6
.6
)
 
26
 (8
.0
)
18
 (6
.2
)
27
 (9
.4
)
 
 
 
IIB
 
12
5 
(1
3.
8)
63
 (1
5.
5)
62
 (1
2.
5)
 
40
 (1
2.
3)
41
 (1
4.
1)
44
 (1
5.
3)
 
 
 
III
 
48
 (5
.3
)
21
 (5
.2
)
27
 (5
.4
)
 
18
 (5
.5
)
18
 (6
.2
)
12
 (4
.2
)
 
 
 
IV
 
25
1 
(2
7.
8)
12
3 
(3
0.
2)
12
8 
(2
5.
8)
 
79
 (2
4.
3)
95
 (3
2.
8)
77
 (2
6.
7)
 
H
ig
h-
gr
ad
e 
ne
op
la
sm
s 
ex
cl
ud
ed
 
 
 
 
 
 
 
 
E
N
E
TS
 9
64
 
 
 
 .1
4
 
 
 
.0
1
 
 
 
I
29
0
11
2 
(3
8.
6)
17
8 
(6
1.
4)
 
11
5 
(3
9.
7)
87
 (3
0.
0)
88
 (3
0.
3)
 
 
 
IIA
 
14
4
65
 (4
5.
1)
79
 (5
4.
9)
 
62
 (4
3.
1)
33
 (2
2.
9)
49
 (3
4.
0)
 
 
 
IIB
 
76
36
 (4
7.
4)
40
 (5
2.
6)
 
27
 (3
5.
5)
16
 (2
1.
0)
33
 (4
3.
5)
 
 
 
III
A
 
32
15
 (4
6.
9)
17
 (5
3.
1)
 
9 
(2
8.
1)
11
 (3
4.
4)
12
 (3
7.
5)
 
 
 
III
B
 
17
7
85
 (4
8.
0)
92
 (5
2.
0)
 
56
 (3
1.
6)
63
 (3
5.
6)
58
 (3
2.
8)
 
 
 
IV
 
24
5
12
3 
(5
0.
2)
12
2 
(4
9.
8)
 
73
 (2
9.
8)
96
 (3
9.
2)
76
 (3
1.
0)
 
 
U
IC
C
/A
JC
C
/W
H
O
 2
01
0
84
6
 
 
 
.1
5
 
 
 
.1
5
 
 
 
IA
 
26
6
10
3 
(3
8.
7)
16
3 
(6
1.
3)
 
10
6 
(3
9.
8)
81
 (3
0.
5)
79
 (2
9.
7)
 
 
 
IB
 
14
1
58
 (4
1.
1)
83
 (5
8.
9)
 
56
 (3
9.
7)
36
 (2
5.
5)
49
 (3
4.
7)
 
 
 
IIA
 
68
36
 (5
2.
9)
32
 (4
7.
1)
 
26
 (3
8.
2)
17
 (2
5.
0)
25
 (3
6.
8)
 
 
 
IIB
 
10
9
52
 (4
7.
7)
57
 (5
2.
3)
 
34
 (3
1.
2)
36
 (3
3.
0)
39
 (3
5.
8)
 
 
 
III
 
43
17
 (3
9.
5)
26
 (6
0.
5)
 
17
 (3
9.
5)
16
 (3
7.
2)
10
 (2
3.
3)
 
 
 
IV
 
21
9
10
5 
(4
7.
9)
11
4 
(5
2.
1)
 
67
 (3
0.
6)
86
 (3
9.
3)
66
 (3
0.
1)
* 
C
on
tin
uo
us
 d
at
a 
w
er
e 
de
sc
rib
ed
 a
s 
th
e 
m
ea
n 
an
d 
st
an
da
rd
 d
ev
ia
tio
n 
(S
D
) o
r 
m
ed
ia
n 
an
d 
25
th
 t
o 
75
th
 p
er
ce
nt
ile
s 
an
d 
w
er
e 
co
m
pa
re
d 
by
 K
ru
sk
al
l–
W
al
lis
 t
es
ts
. C
at
eg
or
ic
al
 d
at
a 
w
er
e 
de
sc
rib
ed
 a
s 
co
un
ts
 a
nd
 p
er
-
ce
nt
ag
es
 a
nd
 w
er
e 
co
m
pa
re
d 
by
 x
2  
te
st
s.
 A
ll 
st
at
is
tic
al
 t
es
ts
 w
er
e 
tw
o-
si
de
d.
 A
JC
C
 =
 A
m
er
ic
an
 J
oi
nt
 C
an
ce
r 
C
om
m
itt
ee
; E
N
E
TS
 =
 E
ur
op
ea
n 
N
eu
ro
en
do
cr
in
e 
Tu
m
or
 S
oc
ie
ty
; P
D
E
C
 =
 p
oo
rly
 d
iff
er
en
tia
te
d 
en
do
cr
in
e 
ca
rc
in
om
a 
(W
H
O
 2
00
0 
C
la
ss
 3
); 
U
IC
C
 =
 In
te
rn
at
io
na
l U
ni
on
 f
or
 C
an
ce
r 
C
on
tr
ol
; W
D
E
C
 =
 w
el
l-d
iff
er
en
tia
te
d 
en
do
cr
in
e 
ca
rc
in
om
a 
(W
H
O
 2
00
0 
C
la
ss
 2
); 
W
D
E
T 
=
 w
el
l-d
iff
er
en
tia
te
d 
en
do
cr
in
e 
tu
m
or
 (W
H
O
 2
00
0 
C
la
ss
 1
); 
W
H
O
 =
 W
or
ld
 H
ea
lth
 O
rg
an
iz
at
io
n.
† 
O
th
er
 r
ar
e 
sy
nd
ro
m
es
 in
cl
ud
e 
th
os
e 
w
ith
 u
nr
eg
ul
at
ed
 p
ro
du
ct
io
n 
of
 a
dr
en
oc
or
tic
ot
ro
pi
c 
ho
rm
on
e,
 c
al
ci
to
ni
n,
 g
hr
el
in
, g
ro
w
th
 h
or
m
on
e–
re
le
as
in
g 
fa
ct
or
, p
ar
at
hy
ro
id
 h
or
m
on
e,
 o
r 
so
m
at
os
ta
tin
.
‡ 
D
ef
in
iti
on
s 
in
 a
cc
or
da
nc
e 
w
ith
 S
ol
ci
a 
et
 a
l. 
(1
8)
.
§ 
M
ito
tic
 c
ou
nt
 w
as
 e
xp
re
ss
ed
 a
s 
pe
r 
10
 h
ig
h 
po
w
er
 f
ie
ld
 a
nd
 K
i6
7 
in
de
x 
as
 a
 p
er
ce
nt
ag
e 
of
 2
00
0 
ce
lls
 (3
).
T
ab
le
 2
 (
C
o
n
ti
n
u
ed
).
jnci.oxfordjournals.org   JNCI | Articles 769
The distribution of the type of syndrome was independent of sex, 
although it was statistically significantly dependent on age (P = 
.04), for which insulinomas and Zollinger–Ellison syndrome/
gastrinomas were more frequent among younger vs older patients 
and glucagonomas and serotonin-producing “carcinoid” more 
frequent among older vs younger patients. The tumor site was 
differently distributed between the sexes (P < .001) and age groups 
(P = .02), with the entire organ involvement being more frequently 
observed among females and younger patients. Curative surgery 
more likely occurred in females (P < .001), though with no statis-
tically significant difference by age. Along the same lines, the type 
of surgery performed was differently distributed among the sexes. 
Finally, male patients proved to have statistically significantly 
larger tumor size (P = .03), higher WHO 2000 class (P < .001), 
Ki67 index (P < .001), ENETS/WHO 2010 grade (P = .006), and 
stage (P = .03) compared with females. WHO 2000 class and 
ENETS/WHO 2010 stage was also dependent on age (P = .005 
and .03, respectively).
Survival and Staging Systems: Head to Head Comparison
A comparison was run on the series with or without high-grade 
neoplasms, as required by UICC/AJCC (Table 3 and Supplementary 
Table 1, available online). Among 1064 patients, the median time 
of follow-up was 67 months (25th to 75th percentiles = 30–125); 
262 patients died of their cancer, which corresponded to a death rate 
of 4.5 deaths per 100 persons per year (95% CI = 4.0 to 5.1). The 
cumulative survival at 5 years was 82.7% (95% CI = 80.0% to 85.2%) 
and 73.6% (95% CI = 69.7% to 77.0%) at 10 years (Figure 1, A). 
Survival curves for different tumor types show improved survival 
for insulinoma patients vs patients with other functioning or non-
functioning neoplasms (Figure 1, B and Table 4; for the survival 
curves in different types of functioning neoplasm types, see 
Supplementary Figure 1, available online).
Of 1072 neoplasms, data for 1034 included the ENETS TNM 
stage and data on the UICC/AJCC/WHO 2010 TNM stage were 
available for 903 neoplasms. Both TNM staging systems were 
available in 891 patients and were statistically significantly associ-
ated with tumor mortality (P < .001 for both staging systems) 
(Table 3 and Figure 2). For the ENETS TNM stage, death rates 
uniformly progressed from class I to IIIA, were lower in class IIIB, 
increased further in class IV, and statistically significant differences 
were observed between each subsequent stage, although stages IIA 
and IIB were not statistically significantly different. Conversely, 
for UICC/AJCC/WHO 2010 TNM stage, death rates increased 
from class IA to IIA and remained stable until class III at which 
point death rates markedly increased in class IV. Statistically 
significant differences were observed only between stages IA and 
IB (death rate = 0.1 vs 0.7, respectively; HR of death = 5.25, 95% 
CI = 1.1 to 25.3, P = .04), stages IB and IIA (death rate = 0.7 and 
3.7, respectively; HR of death = 5.1, 95% CI = 2.1 to 12.8, P < .001), 
and stages III and IV (death rate = 3.4 and 12.0, respectively; HR 
of death = 3.3, 95% CI = 1.7 to 6.5, P = .001) (Table 3 and Figure 3). 
Grouping stages (for the ENETS system, stages IIA–IIB were 
grouped in stage II and stages IIIA–IIIB were grouped in stage III; 
for the UICC/AJCC/WHO 2010 system, stages IA–IB grouped in 
stage I and stages IIA–IIB in stage II) in four stage classes (I–IV) 
demonstrated statistically significant and progressive separation in 
the four classes by the ENETS TNM (stage I served as the refer-
ence; stage II HR of death = 16.23, 95% CI = 2.14 to 123, P = .007; 
stage III HR of death = 51.81, 95% CI = 7.11 to 377, P < .001; 
stage IV HR of death = 160, 95% CI = 22.30 to 1143, P < .001) in 
contrast to the overlap of stages II–III observed when the UICC/
AJCC/WHO 2010 TNM was applied to the same data (stage I 
served as the reference; stage II HR of death = 9.57, 95% CI = 4.62 
to 19.88, P < .001; stage III HR of death = 9.32, 95% CI = 3.69 to 
23.53, P = .94; stage IV HR of death = 30.84, 95% CI = 15.62 to 
60.87, P < .001) (Table 3 and Figure 3).
The Royston explained variation for prediction of tumor-
related death was similar for both TNM systems, indicating good 
model performance (Royston explained variation for ENETS = 
0.59, 95% CI = 0.49 to 0.68 vs UICC/AJCC/WHO 2010 = 0.59, 
95% CI = 0.48 to 0.69) (Table 3). Nonetheless, the discrimination 
ability for tumor-related death measured by the Harrell C and the 
Somer D statistics were slightly better for the ENETS TNM 
relative to the UICC/AJCC/WHO 2010 TNM (Harrell C statistic 
for ENETS TNM vs UICC/AJCC/WHO 2010 TNM = 0.8 vs 
0.79; Somer D statistic for ENETS TNM vs UICC/AJCC/WHO 
2010 TNM = 0.69 vs 0.65) (Table 3). The difference in discrimi-
nation ability for tumor-related death between the two TNMs 
remained similar when high-grade neoplasms were excluded from 
the analysis, as required by the UICC/AJCC/WHO 2010 TNM 
(Harrell C statistic for ENETS TNM vs UICC/AJCC/WHO 
2010 TNM = 0.79 vs 0.67; Somer D statistic for ENETS TNM vs 
UICC/AJCC/WHO 2010 TNM = 0.67 vs 0.62) (Supplementary 
Table 1 available on line). Overlap of the IA–IB and IIA–IIB con-
secutive stages was also observed when high-grade neoplasms were 
excluded from analysis of tumor-related, death and UICC/AJCC/
WHO 2010 TNM vs the ENETS TNM Harrell C and Somer D 
statistics values also remained similar when compared with 
analyses that included high-grade neoplasms (Supplementary 
Table 1 and Supplementary Figure 2, available online). When 
high-grade neoplasms were excluded from the analysis, the differ-
ence in discriminatory ability for tumor-related death of the two 
TNMs was further confirmed when stages were grouped into four 
classes and the Harrel C and Somer D statistics were calculated 
(stages I–IV: ENETS TNM vs UICC/AJCC/WHO 2010 Harrell 
C statistic = 0.78 vs 0.77; Somer D statistic = 0.63 vs 0.60) 
(Supplementary Table 1 and Supplementary Figure 3, available 
online).
Further sensitivity analyses of the role of both TNM staging 
systems on tumor-free survival were performed for each center 
separately, and with Cox models stratified by study center, age, 
and/or sex (data not shown). All tests provided results consistent 
with those observed for the whole series, and, although with 
higher variability, the ENETS TNM staging system proved to be 
more sensitive in predicting tumor-free survival when compared 
with the UICC/AIJCC/WHO 2010 TNM system. Furthermore, 
a sensitivity analysis on the role of both tumor staging systems on 
overall survival gave results comparable with those of Table 3, 
with similar Royston explained variation for prediction of tumor-
related death for both TNM systems and slightly better discrim-
ination ability measured by the Harrell C and the Somer D 
statistics for the ENETS system (Supplementary Table 2, avail-
able online).
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Predictors of Tumor-Related Death: Cutoff Identification 
and Univariable Analysis
The relationship between potential risk factors and tumor-related 
death and corresponding mortality rates were investigated. In 
ROC analysis, optimal cutoffs for prediction of tumor-related 
death at 5 years were identified for size (≥3 cm, ROC-AUC = 
0.65), number of positive lymph nodes (≥1, AUC = 0.67), number 
of mitoses (≥2, AUC = 0.77), and Ki67 index (≥4.85, AUC = 0.81) 
(Table 4). The association of each dichotomized marker and 
tumor-related death was assessed during the long-term follow-up 
in the test sample. Their performance was suboptimal for size 
(Harrell C statistic = 0.61, 95% CI = 0.56 to 0.66), number of 
positive lymph nodes (Harrell C statistic = 0.68, 95% CI = 0.62 
to 0.65), and number of mitoses (Harrell C statistic = 0.68, 95% 
CI = 0.61 to 0.76), whereas performance was relatively better 
for Ki67 index (Harrell C statistic = 0.73, 95% CI = 0.68 to 
0.78).
With the exception of the multiple tumors variable, all predic-
tors were statistically significantly associated with tumor-related 
death at follow-up (Table 4). Specifically, death rates were higher 
for older vs younger patients (death rate for older patients = 4.6, 
95% CI = 3.7 to 5.8 vs death rate for younger patients = 2.5, 95% 
CI = 1.9 to 3.2), males vs females (death rate for males = 4.1, 95% 
CI = 3.4 to 5.0 vs death rate for females = 3.0, 95% CI = 2.5 to 3.6), 
sporadic vs non-sporadic tumors (death rate for sporadic tumors = 3.4, 
95% CI = 2.9 to 4.0 vs death rate for non-sporadic tumors with 
multiple endocrine neoplasia syndrome type I = 0.5, 95% CI = 0.1 to 
3.6 and with Von Hippel-Lindau syndrome = 2.5, 95% CI = 0.6 to 10), 
and nonfunctioning vs functioning tumors (death rate for non-
functioning tumors = 4.5, 95% CI = 3.9 to 5.3 vs death rate for 
functioning tumors = 1.8, 95% CI = 1.3 to 2.5; Table 4). Among func-
tioning tumors, the lowest death rate was observed for insulinomas 
(death rate = 0.7, 95% CI = 0.4 to 1.3), the highest for neoplasms asso-
ciated with the carcinoid syndrome (death rate = 6.4, 95% CI = 2.4 to 
17.0) (Table 4). Death rates were also relatively higher when curative 
surgery could not be performed, when a single tumor was present, 
and when the tumor involved the head of the pancreas. The death rate 
increased as WHO 2000 class, ENETS/WHO 2010 grade (Figure 4), 
tumor size, number of positive lymph nodes, mitotic cell counts, or 
Ki67 index increased (Supplementary Figure 4, available online).
Predictors of Tumor-Related Death: Multivariable Analysis
Although statistically significant at univariable analysis, mitotic cell 
counts and number of lymph nodes yielded too many missing 
values and were not considered for the multivariable analysis. 
Given the high collinearity between WHO 2000 class and stage on 
the one hand, and between Ki67 index and ENETS/WHO 2010 
grade (in both cases largely expected) on the other, six non-nested 
multivariable models were fitted (models 1.1, 1.2, 2.1, 2.2, 3.1, and 
3.2), including the ENETS and UICC/AJCC/WHO 2010 TNM 
stages and the noncollinear predictors (Table 5; for details on the 
risk associated with each category of the considered predictors per 
multivariable model, see Supplementary Table 3, available online). 
It was expected that the optimal model would provide the highest 
explained variation, shrinkage coefficient, and the Harrell C statistic, 
and the lowest Akaike information criterion.
All models performed remarkably well, with well-explained 
variations, a high shrinkage coefficient, and optimal discrimination 
(both by Harrell C and graphically), the best performance being 
observed for both models with the ENETS TNM stage (model 
1.1, Akaike Information Criterion = 1357.85; Royston explained 
variation = 0.77, 95% CI = 0.74 to 0.8; shrinkage coefficient = 0.93; 
Harrell C statistic = 0.88; model 1.2 Akaike Information Criterion = 
1360.48; Royston explained variation = 0.75, 95% CI = 0.69 to 
0.84; shrinkage coefficient = 0.93, Harrell C statistic = 0.87) (Table 5) 
also including either the ENETS-WHO 2010 grade or Ki67 
index. ENETS stage, UICC/AJCC/WHO 2010 stage, curative 
surgery, ENETS/WHO 2010 grade, and Ki67 index were consis-
tently identified as independent predictors of the outcome in the 
six models (Supplementary Table 3, available online). However, 
when considering the variable “stage,” the UICC/AJCC/WHO 
2010 TNM displayed unusually elevated hazard ratios of death 
with extremely wide 95% confidence intervals (model 2.1: stage IB 
HR = 6.04, 95% CI = 0.6 to 52.52, P = .10; stage IIA HR = 23.86, 
95% CI = 2.87 to 198.57, P = .003; stage IIB HR = 24.64, 95% 
CI = 3.06 to 198.58, P = .003; stage III HR = 21.46, 95% CI = 2.47 
Figure 1. Kaplan–Meier survival curves for pancreatic neuroendocrine 
neoplasms (n = 1064) overall and by functioning status. A) The Kaplan–
Meier survival curve is shown with the number of patients at risk. B) 
The neoplasms were grouped by functioning status, and Kaplan–Meier 
survival was calculated. Continous 95% confidence intervals are shown. 
The number of patients at risk is given below the graph. INS = insulinoma, 
NON = nonfunctioning neoplasms, OTH = other rare syndromes include 
those with unregulated production of adrenocorticotropic hormone, 
calcitonin, ghrelin, growth hormone–releasing factor, parathyroid 
hormone, or somatostatin.
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Table 4. Other predictors of tumor-related death among 891 patients with pancreatic neuroendocrine neoplasms for whom data was 
available
Variable
Tumor-related  
deaths, No. (%)
Death rate per  
100 person-years  
(95% CI) HR (95% CI) P*
Age, y    .006
 12–47 55 (14.5) 2.5 (1.9 to 3.2) 1.0 (referent)
 48–61 74 (21.6) 3.7 (3.0 to 4.7) 1.49 (1.05 to 2.12) .02
 62–90 72 (20.9) 4.6 (3.7 to 5.8) 1.73 (1.22 to 2.46) .002
Sex    .04
 Female 97 (17.2) 3.0 (2.5 to 3.6) 1.0 (referent)
 Male 104 (20.4) 4.1 (3.4 to 5.0) 1.22 (1.01 to 1.76)
Genetic status    .02
 Multiple endocrine neoplasia syndrome type 1 1 (2.8) 0.5 (0.1 to 3.6) 1.0 (referent)
 Von Hippel–Lindau syndrome 2 (14.3) 2.5 (0.6 to 10) 4.78 (0.43 to 52.79) .20
 Sporadic 171 (19.7) 3.4 (2.9 to 4.0) 6.77 (0.95 to 48.34) .06
Functioning tumor    <.001
 No 162 (22.1) 4.5 (3.9 to 5.3) 1.0 (referent)
 Yes 39 (11.8) 1.8 (1.3 to 2.5) 0.43 (0.30 to 0.61)
Type of syndrome    <.001
 Carcinoid 4 (26.7) 6.4 (2.4 to 17.0) 1.0 (referent)
 Glucagonoma 5 (22.7) 4.4 (1.8 to 10.6) 0.67 (0.18 to 2.48) .55
 Insulinoma 11 (4.9) 0.7 (0.4 to 1.3) 0.11 (0.04 to 0.36) <.001
 Verner–Morrison 6 (31.6) 4.3 (1.9 to 9.6) 0.70 (0.20 to 2.47) .58
 Zollinger–Ellison 10 (27.0) 4.7 (2.5 to 8.8) 0.43 (0.23 to 2.31) .59
 Other† 3 (18.7) 3.7 (1.2 to 11.4) 0.57 (0.13 to 2.54) .46
 Nonfunctioning 139 (22.3) 4.3 (3.7 to 5.1) 0.66 (0.24 to 1.77) .41
Type of syndrome (grouped)    <.001
 Nonfunctioning 162 (22.1) 4.5 (3.9 to 5.3) 1.0 (referent)
 Insulinoma 11 (4.9) 0.7 (0.4 to 1.3) 0.18 (0.09 to 0.32) <.001
 Other† 28 (25.7) 4.6 (3.2 to 6.7) 1.06 (0.71 to 1.59) .77
Curative surgery    <.001
 No 109 (41.4) 12.2 (10.1 to 14.7) 1.0 (referent)
 Yes 88 (11.3) 1.9 (1.5 to 2.3) 0.17 (0.13 to 0.23)
Type of surgery    <.001
 Enucleation 4 (2.2) 0.3 (0.1 to 0.9) 1.0 (referent)
 Left pancreatectomy 66 (18.7) 3.4 (2.6 to 4.3) 9.90 (3.61 to 27 to 19) <.001
 Middle pancreatectomy 2 (3.0) 0.5 (0.1 to 2.0) 1.49 (0.27 to 8.11) .65
 Pancreatic duodenectomy/Whippple resection 41 (16.3) 3.0 (2.2 to 4.0) 8.74 (3.13 to 24.40) <.001
 Total pancreatectomy 6 (20.7) 6.3 (2.8 to 14.1) 16.24 (4.58 to 57.66) <.001
 Unknown 82 (45.3) 11.4 (9.2 to 14.2) 32.31 (11.84 to 88.22) <.001
Multiple tumors    .09
 No 152 (17.5) 3.1 (2.7 to 3.6) 1.0 (referent)
 Yes 3 (6.4) 1.4 (0.4 to 4.3) 0.42 (0.13 to 1.32)
Tumor site    .046
 Body 23 (10.7) 2.1 (1.4 to 3.) 1.0 (referent)
 Body–tail 69 (20.5) 3.5 (2.8 to 4.4) 1.73 (1.08 to 2.77) .02
 Head 73 (19.8) 3.8 (3.1 to 4.8) 1.83 (1.15 to 2.93) .01
 Head–body–tail 2 (11.8) 2.3 (0.6 to 9.2) 1.10 (0.26 to 4.66) .90
WHO 2000 class    <.001
 1 (WDET) 12 (2.5) 0.4 (0.2 to 0.7) 1.0 (referent)
 2 (WDEC) 139 (28.7) 5.8 (4.9 to 6.8) 14.39 (7.96 to 26.01) <.001
 3 (PDEC) 40 (57.1) 34.4 (25.2 to 46.9) 75.21 (38.77 to 145) <.001
ENETS/WHO 2010 grade    <.001
 G1 32 (6.6) 1.0 (0.7 to 1.4) 1.0 (referent)
 G2 101 (26.6) 5.1 (4.2 to 6.2) 4.83 (3.24 to 7.20) <.001
 G3 40 (63.5) 32.9 (24.1 to 44.8) 28.74 (17.78 to 46.46) <.001
Tumor size, cm‡    <.001
 <3 36 (7.6) 1.3 (0.9 to 1.8) 1.0 (referent)
 ≥3 151 (29.0) 5.5 (4.7 to 6.5) 4.05 (2.81 to 2.83)
ENETS TNM tumor size, cm    <.001
 ≤2 24 (6.2) 1.1 (0.7 to 1.6) 1.0 (referent)
 2–4 67 (22.7) 3.9 (3.1 to 5.0) 3.55 (2.23 to 6.67) <.001
 >4 96 (30.6) 6.3 (5.2 to 7.7) 5.47 (3.49 to 8.56) <.001
(Table continues)
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to 186.53, P = .005; stage IV HR = 65.46, 95% CI = 8.17 to 524.55, 
P = 0; model 2.2: stage IB HR = 6.38, 95% CI = 0.74 to 55.06, 
P = .09; stage IIA HR = 22.40, 95% CI = 2.74 to 183.35, P = .004; 
stage IIB HR = 23.27, 95% CI = 2.93 to 184.80, P = .003; stage III 
HR = 24.29, 95% CI = 2.88 to 205.17, P = .003; stage IV HR = 
55.62, 95% CI = 7.03 to 439.85, P = .000), thus indicating an 
imprecise predictive ability. When considering the variable grade 
or Ki67 index, the two-tiered system for Ki67 index with the cutoff 
value defined by the ROC curve (<4.85 vs ≥4.85) were independent 
predictors of survival in all fitted models (models 1.2, 2.2, and 3.2). 
Conversely, statistically significant separation between the three 
ENETS grades was observed only in model 3.1 which did not 
include the stage variable, thus indicating its efficacy in the absence 
of staging information (stage G2 HR = 6.18, 95% CI = 2.84 
to 13.45, P = .02; stage G3 HR = 5.84, 95% CI = 1.95 to 15.43, 
P = .001).
Discussion
TNM staging represents a simple and accurate instrument for 
death-risk assessment and patient management at diagnosis, 
provided, it accurately reflects the biology and natural history of 
the cancer for which it was designed. Evidence is essential for 
TNM development (22), and this is dramatically true for rare 
“orphan” cancers (23). We tested two TNM staging systems to 
determine which was superior in terms of performance when a 
large series of pancreatic neuroendocrine neoplasms was used. All 
results were resistant to a series of sensitivity analyses.
Our data indicate that the ENETS TNM is superior in perfor-
mance to the UICC/AJCC/WHO 2010 TNM and is more accu-
rate. We observed some differences in distribution of sex and age 
across the ENETS staging system, whereas this was not observed 
for the UICC/AJCC/WHO 2010 TNM. Cox regression analysis 
showed that only the ENETS TNM perfectly allocated patients in 
four risk groups that were statistically significantly different for 
death risk and almost equally populated, whereas the UICC/AJCC/ 
WHO 2010 TNM compressed the disease into three differently 
populated classes with most patients being in stage I, in the equally 
populated stages II and III (which were similar in terms of death 
risk) and in stage IV. Furthermore, multivariable modeling demon-
strated that although both TNM systems’ stages resulted in inde-
pendent predictors of survival, the UICC/AJCC/WHO 2010 
TNM stages consistently showed very large 95% confidence inter-
vals per stage, indicating its inconsistent prediction ability. This 
latter observation deserves one further comment. The fact that the 
UICC/AJCC/WHO 2010 TNM staging results an independent 
predictor of survival at multivariable analysis indicates that mea-
suring the cancer extent is per se relevant, as confirmed by a recent 
single series investigation (14). This does not necessarily translate 
into an effective description of cancer course, as demonstrated 
here. Building a TNM system requires the use of parameters 
proven as important for treatment-aimed patient stratification. 
This appears not to be the case for the UICC/AJCC/WHO 2010 
TNM, fitting more the aggressive course of ductal adenocarcinoma 
(smaller size and early invasion of nearby tissues/vessels) rather 
than the slow malignant pace of neuroendocrine neoplasms (larger 
Variable
Tumor-related  
deaths, No. (%)
Death rate per  
100 person-years  
(95% CI) HR (95% CI) P*
Positive lymph nodes‡    <.001
 <1 35 (8.1) 1.3 (0.9 to 1.8) 1.0 (referent)
 ≥1 73 (27.6) 5.3 (4.2 to 6.7) 4.03 (2.69 to 6.05)
Mitotic count‡    <.001
 <2 28 (10.8) 1.3 (0.9 to 2.0) 1.0 (referent)
 ≥2 52 (32.5) 5.9 (4.5 to 7.8) 4.30 (2.69 to 6.87)
Ki67 index‡    <.001
 <4.8 48 (8.3) 1.3 (1.0 to 1.7) 1.0 (referent)
 ≥4.8 124 (40.0) 9.5 (8.0 to 11.3) 6.81 (4.87 to 9.54)
Ki67 (ENETS/WHO 2010)    <.001
 0–2 38 (8.0) 1.2 (0.9 to 1.7) 1.0 (referent)
 >2–20 96 (27.5) 5.4 (4.4 to 6.6) 4.25 (2.92 to 6.21) <.001
 >20 38 (64.5) 33.9 (24.7 to 46.6) 24.64 (15.46 to 39.26) <.001
Ki67 modified§    <.001
 0–5 69 (10.6) 1.7 (1.3 to 2.2) 1.0 (referent)
 >5–20 65 (37.1) 8.1 (6.3 to 10.3) 4.56 (3.24 to 6.43) <.001
 >20 38 (64.4) 33.9 (24.7 to 46.6) 18.02 (12.92 to 27.24) <.001
* Two-sided Cox univariable analysis was done. CI = confidence interval; ENETS = European Neuroendocrine Tumor Society; HR = hazard ratio; PDEC = poorly 
differentiated endocrine carcinoma (WHO 2000 Class 3); WDEC = well-differentiated endocrine carcinoma (WHO 2000 Class 2); WDET = well-differentiated 
endocrine tumor (WHO 2000 Class 1); WHO = World Health Organization.
† Other rare syndromes include those with unregulated production of adrenocorticotropic hormone, calcitonin, ghrelin, growth hormone–releasing factor, parathy-
roid hormone, or somatostatin.
‡ Cutoff values derived from the receiver operating curve analysis identifying the optimal cutoff for predicting 5-year tumor mortality. The Ki67 index was calculated 
as a percentage of 2000 cells that stained positively for Ki67 (3).
§ Modifications to the Ki67 staining analysis were in accordance with that of Scarpa et al. (12) with grading definitions as G1 = ≤5%, G2 = >5–20%, and G3 = >20%.
Table 4 (Continued).
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size, rare invasion, and late course to metastasis) (24). Indeed, the 
perfect patient stratification in four risk classes by the ENETS 
TNM allows for the progressive approach to more aggressive 
treatment options, as supported by current guidelines (25–27).
Ki67 grading is a useful instrument for the management of 
patients with neuroendocrine tumors (27). The ENETS/WHO 
2010 grade and a two-step proliferation grading by Ki67 were 
independent predictors of outcome in a multivariable analysis, 
confirming previously published analysis of single institution series 
(9,10,28) and strongly supporting the adoption of the recent 
WHO 2010 classification (17). Of note, the WHO grading 
acquires outmost efficacy in the absence of staging information, 
supporting its use for small biopsy analysis and in the absence of 
other clinical information, which is a frequent event in daily 
pathology practice. The recent proposal of 5% Ki67 as cutoff for 
G1 (12) fits our finding of 4.8% Ki67 at analysis of data under the 
ROC curve. However, the substantial efficacy overlap of both 
systems observed in this series does not justify a change in the 
current WHO grading, which is otherwise meant for all sites of the 
gut. In view of the large range for G2 grading (3% to <20%), as 
defined by the ENETS-WHO 2010 grading, this finding suggests 
5% as the actual border for the more aggressive disease. This other 
piece of information may result in more accurate tailoring of 
therapy to the individual patient.
Potentially curative surgery resulted also in an independent 
predictor of outcome at multivariable analysis in the present series. 
This observation strongly supports the adoption of aggressive 
strategies for curative surgery in the treatment of neuroendocrine 
neoplasms of the pancreas, as previously emphasized (29). It may 
be interpreted consequently that a more aggressive surgical attitude 
should be pursued even for small size (≤2 cm) lesions, especially in 
the sporadic setting. Along these lines, the ROC curve analysis for 
size identified 3 cm as a possible cutoff for more aggressive disease, 
in part supporting previous observation made on the basis of a 
limited case series (9,10,12). Caution should be used, however, 
in interpreting the effect of treatment in an observational study. 
A higher malignancy of the tumor might in fact hamper the use or 
success of surgery.
Figure 2. Death incidence and survival by European Neuroendocrine 
Tumor Society (ENETS) and the International Union for Cancer 
Control/American Joint Cancer Committee/World Health Organization 
(UICC/AJCC/WHO) 2010 TNM staging systems. A) Tumor-related 
death incidence for 891 patients by ENETS stage is shown with 95% 
confidence intervals (error bars). B) Kaplan–Meier survival curves for 
patients (n = 891) by ENETS TNM stage. Continous 95% confidence 
intervals are shown. The number of patients at risk is given below the 
curve. C) Tumor-related death incidence for 891 patients by AJCC/
UICC/WHO 2010 TNM stage is shown with 95% confidence intervals 
(error bars). D) Kaplan–Meier survival curves for patients (n = 891) by 
AJCC/UICC/WHO 2010 TNM stage. Continous 95% confidence inter-
vals are shown. The number of patients at risk is given below the 
curve.
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Figure 3. Death incidence and survival by European Neuroendocrine 
Tumor Society (ENETS) and the International Union for Cancer Control/
American Joint Cancer Committee/World Health Organization (UICC/
AJCC/WHO) 2010 TNM staging systems when stages were grouped 
into four classes. A) Tumor-related death incidence for 891 patients by 
ENETS stage is shown with 95% confidence intervals (error bars). B) 
Kaplan–Meier survival curves for patients (n = 891) by ENETS TNM 
stage. Continuous 95% confidence intervals are shown. The number of 
patients at risk is given below the curve. C) Tumor-related death inci-
dence for 891 patients by AJCC/UICC/WHO 2010 TNM stage is shown 
with 95% confidence intervals (error bars). D) Kaplan–Meier survival 
curves for patients (n = 891) by AJCC/UICC/WHO 2010 TNM stage. 
Continuous 95% confidence intervals are shown. The number of 
patients at risk is given below the curve.
Figure 4. Kaplan–Meier survival curves of 926 neoplasms by the 
European Neuroendocrine Tumor Society /World Health Organization 
2010 grade. Continuous 95% confidence intervals are shown. The 
number of patients at risk is given below the curve.
The cutoff number of lymph nodes identified as potentially 
being associated with adverse survival, as identified by ROC curve 
analysis, was one. This indicates that a single lymph node metasta-
sis is per se a clinically significant adverse event. However, the 
ENETS TNM stage IIIB (any T, N1, M0) unexpectedly identified 
patients with better fare than patients in Stage IIIA (T4, N0, M0). 
This could be explained by size differences of the two patient 
groups (N.39 for IIIA and N.156 for IIIB), or by differences in 
surgical techniques and lymph node sampling, or may simply 
indicate that T4 is per se a more adverse parameter than N1. 
Alternatively, given the T definition (see Table 1), stage IIIA may 
well contain a large number of patients not amenable to curative 
surgery. These observations suggest the need for TNM adjust-
ment as recently proposed (12). Along these lines and more impor-
tantly, when grouped into a single stage III class, the separation in 
risk group was statistically significant and progressive, confirming 
the efficacy of the ENETS TNM staging. Thus, a simplification 
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of the ENETS staging system into four single stage classes only is 
suggested. In contrast, the UICC/AJCC/WHO 2010 TNM stage 
system was unable to separate intermediate groups, possibly 
because of the extremely broad T definition of stages IIA and IIB.
Other interesting findings emerged by the descriptive and uni-
variable analysis of this series, specifically, the overall good perfor-
mance of neuroendocrine neoplasm patients with net separation of 
insulinomas and the substantial course overlap of nonfunctioning 
and other non-insulinoma functioning neoplasms. This corre-
sponds with the somehow unique signature of insulinomas as 
compared with other pancreas neoplasms (9,30). The same applies 
for high-grade G3 neoplasms, which, similar to the few published 
series, fare the worst and represent a minority of patients (ie, less 
than 10% of this series) (24,31,32). The most typical profile of the 
patient with sporadic neuroendocrine neoplasm is male and of the 
6th decade, whereas younger female are patients with familial 
(most likely multiple endocrine neoplasia syndrome type 1) disease. 
Adverse features observed were being male, older age, non-curative 
surgery, and sporadic nonfunctioning neoplasms, again confirming 
previously reported data from the registry and single institution 
series (11,12,28).
This cohort is the largest ever published on neuroendocrine 
neoplasms of the pancreas listing such detailed information to our 
knowledge. This series results from the retrospective collection of 
neoplastic tissues obtained at surgery from 11 European Insti-
tutions known as referral centers for oncology, endocrinology, 
gastroenterology/pancreatology, and pancreas surgery for neuro-
endocrine neoplasm patients. To reduce the various selection bias 
expected and to reflect on the daily clinical practice, our strategy 
was to collect data representing all settings of presentation/cure of 
this type of patient. Certainly, and this is largely expected, the 
most obvious and positive effect is the overall elevated survival 
observed here at 5 and 10 years, likely depending on a mixture of 
early diagnosis, accurate surgery, tailored medical therapy, and 
effective follow-up. The combination of such positive features 
goes along with what is recommended for the cure of rare cancer 
disease and for neuroendocrine neoplasms specifically. Along these 
lines, the widespread adoption of common guidelines based on the 
WHO classification together with the universal health system in 
European countries may both explain the overall excellent survival 
reported here.
The major limitation of this study is its retrospective nature, 
which implies some degree of variation in collecting relevant data. 
For example, surgical techniques and lymph node sampling may 
slightly vary among different institutions and surgical teams, 
potentially resulting in different nodal status definition. Also, the 
interpretation of Ki67 staining of cancer cells may slightly vary in 
different pathology laboratories and by the pathologists’ expertise, 
leading to differential proliferation grading assessments. 
Additionally, variability in treatment at different centers may have 
influenced patient survival. Collection of relevant data in a large 
prospective series with uniform protocols for data entry is needed 
to confirm our findings.
In conclusion, neuroendocrine cancer patient survival depends 
on multiple factors, certainly one of the most important being 
therapy. Accurate selection of patients for therapy is needed when 
the extent of neuroendocrine cancer disease is measured (33). This Ta
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can be achieved only by accurate surgical staging. Our data suggest 
the ENETS TNM staging system as superior and support its use 
in current clinical practice.
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